中東およびアフリカの創薬市場における人工知能 (AI)、アプリケーション別 (新薬候補、薬物の最適化と転用、前臨床試験および承認、薬物モニタリング、新しい疾患関連ターゲットと経路の発見、疾患メカニズムの理解、情報の集約と統合、仮説の形成と適格性、デノボ薬物設計、古い薬物の薬物ターゲットの発見など)、テクノロジー別 (機械学習、ディープラーニング、自然言語処理など)、薬物タイプ別 (小分子と巨大分子)、提供内容別 (ソフトウェアとサービス)、適応症別 (免疫腫瘍学、神経変性疾患、心血管疾患、代謝性疾患など)、最終用途別 (開発業務受託機関 (CRO)、製薬およびバイオテクノロジー企業、研究センターおよび学術機関など) 業界動向と2029年までの予測。
中東およびアフリカの創薬市場における人工知能 (AI) の分析と洞察
人工知能 (AI) は、ヘルスケア業界では利益を生む技術になると期待されています。AI の導入により、医薬品製造プロセスにおける研究開発ギャップが縮小し、ターゲットを絞った医薬品の製造に役立ちます。そのため、バイオ医薬品企業は市場シェアの拡大に AI を活用しています。医薬品発見のための AI は、機械を使用して人間の知能をシミュレートし、医薬品開発プロセスにおける複雑な課題を解決する技術です。
臨床試験プロセスに AI ソリューションを導入すると、起こり得る障害が排除され、臨床試験のサイクル時間が短縮され、臨床試験プロセスの生産性と精度が向上します。医薬品の発見における AI の技術的進歩と医薬品の発見プロセスにかかる総時間の短縮は、予測期間中の市場の成長を促進する他の要因です。ただし、利用可能なデータの品質が低く一貫性がない場合は、市場の成長が妨げられます。また、テクノロジーに関連するコストの高さと技術的な制限により、市場の成長が抑制されます。
Data Bridge Market Research は、中東およびアフリカの創薬市場における人工知能 (AI) は、予測期間中に 47.1% の CAGR で成長し、2029 年までに 5 億 4,876 万米ドルに達すると予測しています。創薬市場における AI の利用を商業化するための技術進歩が急速に進んでいるため、ソフトウェアは市場で最大の技術セグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 (2019～2014 にカスタマイズ可能) |
|
定量単位 |
売上高は百万米ドル、価格は米ドル |
|
対象セグメント |
アプリケーション別（新薬候補、薬物の最適化と転用、前臨床試験と承認、薬物モニタリング、新しい疾患関連ターゲットと経路の発見、疾患メカニズムの理解、情報の集約と統合、仮説の形成と適格性、新規薬物設計、旧薬の薬物ターゲットの発見など）、テクノロジー別（機械学習、ディープラーニング、自然言語処理など）、薬物タイプ別（小分子と巨大分子）、提供内容別（ソフトウェアとサービス）、適応症別（免疫腫瘍学、神経変性疾患、心血管疾患、代謝性疾患など）、最終用途別（開発業務受託機関（CRO）、製薬・バイオテクノロジー企業、研究センターと学術機関など） |
|
対象国 |
UAE、イスラエル、南アフリカ、サウジアラビア、エジプト、その他の中東およびアフリカ諸国 |
|
対象となる市場プレーヤー |
市場で活動している主要企業としては、NVIDIA Corporation、IBM Corp.、Atomwise Inc.、Microsoft、Benevolent AI、Aria Pharmaceuticals, Inc.、DEEP GENOMICS、Exscientia、Cloud、Insilico Medicine、Cyclica、NuMedii, Inc.、Envisagenics、Owkin Inc.、BERG LLC、Schrödinger, Inc.、XtalPi Inc.、BIOAGE Inc.などが挙げられます。 |
中東およびアフリカの創薬市場における人工知能 (AI) の定義
AI はここ数年、医療技術従事者の注目を集めており、多くの企業や大手研究機関がこれらの技術を臨床で使用できるよう完成させようと取り組んできました。AI (ディープラーニング (DL)、機械学習 (ML)、人工ニューラルネットワーク(ANN) とも呼ばれる) が臨床医をどのように支援できるかを示す最初の商用化デモが現在利用可能です。これらのシステムは、臨床医のワークフローにパラダイムシフトをもたらし、生産性を向上させると同時に、治療と患者のスループットを向上させる可能性があります。創薬のための AI は、機械を使用して人間の知能をシミュレートし、医薬品開発手順における複雑な課題を解決する技術です。臨床試験プロセスに AI ソリューションを採用すると、起こり得る障害が排除され、臨床試験のサイクルタイムが短縮され、臨床試験プロセスの生産性と精度が向上します。そのため、創薬プロセスにおけるこれらの高度な AI ソリューションの採用は、ライフサイエンス業界の関係者の間で人気が高まっています。製薬分野では、新しい化合物の発見、治療ターゲットの特定、カスタマイズされた医薬品の開発に役立ちます。創薬に使用される AI プラットフォームは、さまざまな慢性疾患を治療し、その重症度を最小限に抑える医薬品の発見に関する洞察を得るための実現可能な選択肢となる可能性があります。
中東およびアフリカの創薬市場における人工知能 (AI) の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 慢性疾患の発症率の上昇により、創薬におけるAIの必要性が高まっている
慢性疾患の発症率は世界中で急速に増加しています。米国疾病管理予防センター (CDC) によると、米国の成人 10 人中 6 人が慢性疾患を患っています。さらに、CDC は、心臓病や糖尿病などの慢性疾患が米国における主な死亡原因であることも強調しています。このような統計は、慢性疾患の蔓延が拡大していることと、これらの疾患による死亡率を下げる必要性を明らかにしています。
創薬に使用される AI プラットフォームは、さまざまな慢性疾患を治療し、その重症度を最小限に抑える医薬品の発見に関する洞察を得るための実現可能なオプションであることが証明されています。したがって、これらの要因は、予測期間中に市場の成長の原動力として機能することが期待されています。
- 戦略的コラボレーション、パートナーシップ、製品の発売
AI は、R&D のタイムラインを急速に加速し、医薬品開発をより安価かつ迅速にし、承認の可能性を高めることで、医薬品の発見を変革する可能性があります。AI は医薬品の再利用研究の有効性を高めることもできます。
業界間の提携や協力の増加が市場を牽引しています。医薬品の発見と開発における AI の重要性の高まり、医薬品研究分野における AI 技術を含む研究開発活動への資金の急増が、世界市場の成長を牽引すると予測されています。したがって、業界間の協力やパートナーシップの増加が市場を牽引しています。
拘束
- 技術に関連する高コストと技術的制限
現在のヘルスケア分野は、医薬品や治療法のコスト増加など、いくつかの複雑な課題に直面しており、社会はこの分野で具体的かつ大幅な変化を必要としています。AI の成功は、大量のデータが利用可能かどうかにかかっています。これらのデータは、システムに提供されるその後のトレーニングに使用されるためです。さまざまなデータベース プロバイダーのデータにアクセスすると、企業に追加コストが発生する可能性があります。臨床試験は、特定の病状に対する医薬品の安全性と有効性を人間で確立することを目的としており、6 ～ 7 年の歳月と多額の資金投資が必要です。ただし、これらの試験に参加する分子のうち、承認に成功するのは 10 個のうち 1 個のみであり、これは業界にとって大きな損失です。これらの失敗は、不適切な患者選択、技術要件の不足、インフラストラクチャの貧弱さが原因である可能性があります。したがって、テクノロジーのコスト増加は、市場の成長の抑制要因となっています。
機会
-
研究開発への投資の増加
研究開発活動の増加とクラウドベースのサービスおよびアプリケーションの採用の増加は、市場の成長に有益な機会をもたらすでしょう。
The industry of AI in biopharma continues to grow after a long period of sepsis. This is reflected in the ongoing flow of investments and increase in the number of collaborations between pharmaceutical corporations and AI companies in 2021 to the previous years. The Biopharma industry’s growth is largely influenced by the active engagement of leading pharmaceutical corporations in AI-related investments. The number of scientific publications in the field of AI in Biopharma, and research collaborations between pharma companies and AI-expertise vendors are rapidly increasing, yet, some pharma corporations are still critical of AI applications. ML and AI applications in the pharmaceutical and healthcare industries lead to the formation of a new interdisciplinary field of data-driven drug discovery in healthcare. Thus, rise in investment in R&D activities is acting as an opportunity for market growth.
Challenge
- Lack of skilled professionals
The shortage of skilled professionals is expected to hamper the market growth. The employees have to re-train or learn new skill sets to work efficiently on the complex AI machines to get the desired results for the drug. This challenge that prevents full-fledged adoption of AI in the pharmaceutical industry includes the lack of skilled personnel to operate AI-based platforms, limited budget for small organizations, apprehension of replacing humans leading to job loss, skepticism about the data generated by AI, and the black box phenomenon (that is, how the conclusions are reached by the AI platform). The shortage of skills acts as a major hindrance to drug discovery through AI, discouraging companies to adopt AI-based machines for drug discovery.
As skill demands are too high, it has manifested as a challenge to retain and manage skill-specified professionals. Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. There is an urgent need for the education of professionals for AI-based technology. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. It is therefore apparent that the availability of professionals equipped with adequate skills is challenging the market growth.
Post-COVID-19 Impact on Middle East and Africa Artificial Intelligence (AI) In Drug Discovery Market
The COVID-19 outbreak had a beneficial impact on the expansion of AI in drug discovery industry due to its widespread use by various organizations for the identification as well as screening of existing medicines used in the treatment of COVID-19. AI is useful in detecting active chemicals for the prevention of SARS-CoV, HIV, SARS-CoV-2, influenza virus, and others. During the pandemic, economies all over the world relied on AI-based medication discovery rather than traditional vaccine detection processes, which take years to create and are equally expensive, contributing to the growth of the market.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities to improve the technology involved in the Wireless microphone. With this, the companies will bring advanced and accurate AI software to the market.
Recent Developments
- In March 2022, NVIDIA Corporation launched Clara Holoscan MGX to develop and deploy real-time AI applications. Clara Holoscan MGX expands the Clara Holoscan platform to provide an all-in-one, medical-grade reference architecture, as well as long-term software support, to accelerate innovation in the medical device industry. This will help the company for better AI performance in health sector for surgery, diagnostics, and drug discovery.
- In May 2022, Benevolent AI, a leading clinical-stage AI-enabled drug discovery company, announced that AstraZeneca has selected an additional novel target for Idiopathic Pulmonary Fibrosis (IPF) for its drug development portfolio, resulting in a milestone payment to Benevolent AI. This is the third novel target from the collaboration that has been identified using the Benevolent Platform across two disease areas, IPF and chronic kidney disease, and subsequently validated and selected for portfolio entry by AstraZeneca. This builds upon the recent extension of the collaboration with AstraZeneca to include two new disease areas, systemic lupus erythematosus, and heart failure, signed in January 2022. This has helped the company to make its collaboration stronger.
Middle East and Africa Artificial Intelligence (AI) In Drug Discovery Market Scope
Middle East and Africa Artificial Intelligence (AI) in drug discovery market is segmented into application, technology, drug type, offering, indication, and end use. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
APPLICATION
- Novel Drug Candidates
- Drug Optimization and Repurposing Preclinical Testing and Approval
- Drug Monitoring
- Finding New Diseases Associated Targets and Pathways
- Understanding Disease Mechanisms
- Aggregating and Synthesizing Information
- Formation & Qualification of Hypotheses
- De Novo Drug Design
- Finding Drug Targets of an Old Drug
- Others
Based on application, the market is segmented into novel drug candidates, drug optimization and repurposing preclinical testing and approval, drug monitoring, finding new diseases associated targets and pathways, understanding disease mechanisms, aggregating and synthesizing information, formation & qualification of hypotheses, de novo drug design, finding drug targets of an old drug, and others.
TECHNOLOGY
- Machine Learning (ML)
- Deep Learning (DL)
- Natural Language Processing (NLP)
- Others
Based on technology, the market is segmented into Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and others.
DRUG TYPE
- Small Molecule
- Large Molecule
Based on drug type, the market is segmented into small molecule and large molecule.
OFFERING
- Software
- Services
Based on offering, the market is segmented into software and services.
INDICATION
- Immuno-Oncology
- Neurodegenerative Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Others
Based on indication, the market is segmented into immuno-oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and others.
END USE
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Research Centers and Academic Institutes
- Others
Based on end use, the market is segmented into pharmaceutical & biotechnology companies, Contract Research Organizations (CROs), research centers and academic institutes, and others.
Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market Regional Analysis/Insights
Middle East and Africa Artificial Intelligence (AI) in drug discovery market is analyzed and market size information is provided by application, technology, drug type, offering, indication, and end use.
The countries covered in this market report are U.A.E, Israel, South Africa, Saudi Arabia, Egypt, rest of Middle East and Africa.
- In 2022, Middle East and Africa is dominating due to the increase in government funding. South Africa is expected to grow due to rise in R&D activities for AI in drug discovery.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Artificial Intelligence (AI) In Drug Discovery Market Share Analysis
Middle East and Africa Artificial Intelligence (AI) in drug discovery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Middle East and Africa Artificial Intelligence (AI) in drug discovery market.
この市場で活動している主要企業としては、NVIDIA Corporation、IBM Corp.、Atomwise Inc.、Microsoft、Benevolent AI、Aria Pharmaceuticals, Inc.、DEEP GENOMICS、Exscientia、Cloud、Insilico Medicine、Cyclica、NuMedii, Inc.、Envisagenics、Owkin Inc.、BERG LLC、Schrödinger, Inc.、XtalPi Inc.、BIOAGE Inc.などが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORETSR’S FIVE FORCES
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 THE RISE IN INCIDENCE OF CHRONIC DISEASES PROPELS NEED FOR ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
5.1.2 STRATEGIC COLLABORATIONS, PARTNERSHIPS, AND PRODUCTS LAUNCH
5.1.3 REDUCTION IN TOTAL TIME INVOLVED IN DRUG DISCOVERY PROCESS
5.1.4 ADVANCEMENT OF ARTIFICIAL INTELLIGENCE IN THE HEALTHCARE INDUSTRY
5.2 RESTRAINTS
5.2.1 HIGH COST ASSOCIATED WITH TECHNOLOGY AND TECHNICAL LIMITATIONS
5.2.2 DISADVANTAGES AND RISKS ASSOCIATED WITH AI IN DRUG DISCOVERY
5.2.3 LACK OF AVAILABLE QUALITY DATA
5.3 OPPORTUNITIES
5.3.1 RISE IN THE INVESTMENTS FOR R&D
5.3.2 RISING HEALTHCARE INFRASTRUCTURE
5.3.3 DEVELOPMENT OF NOVEL TOOLS
5.4 CHALLENGES
5.4.1 THE MIDDLE EAST & AFRICA SHORTAGE OF AI TALENT
5.4.2 ETHICAL, LEGAL, AND REGULATORY ISSUES FOR AI ADOPTION IN THE PHARMACEUTICAL SCIENCES
6 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING
6.1 OVERVIEW
6.2 SOFTWARE
6.2.1 INTEGRATED
6.2.2 STANDALONE
6.3 SERVICES
7 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 MACHINE LEARNING (ML)
7.2.1 SUPERVISED LEARNING
7.2.2 UNSUPERVISED LEARNING
7.2.3 REINFORCEMENT LEARNING
7.3 DEEP LEARNING
7.4 NATURAL LANGUAGE PROCESSING (NLP)
7.5 OTHERS
8 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY DRUG TYPE
8.1 OVERVIEW
8.2 SMALL MOLECULE
8.3 LARGE MOLECULE
9 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 NOVEL DRUG CANDIDATES
9.2.1 PREDICT BIOACTIVITY OF SMALL MOLECULE
9.2.2 IDENTIFY BIOLOGICS TARGET
9.2.3 OTHERS
9.3 DRUG OPTIMISATION AND RE-PURPOSING PRE-CLINICAL TESTING AND APPROVAL
9.4 DRUG MONITORING
9.5 AGGREGATING AND SYNTHESIZING INFORMATION
9.6 DE NOVO DRUG DESIGN
9.7 FINDING DRUG TARGETS OF AN OLD DRUG
9.8 FORMATION & QUALIFICATION OF HYPOTHESES
9.9 UNDERSTANDING DISEASE MECHANISMS
9.1 FINDING NEW DISEASE-ASSOCIATED TARGETS AND PATHWAYS
9.11 OTHERS
10 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION
10.1 OVERVIEW
10.2 IMMUNE-ONCOLOGY
10.2.1 BREAST CANCER
10.2.2 LUNG CANCER
10.2.3 COLORECTAL CANCER
10.2.4 PROSTATE CANCER
10.2.5 PANCREATIC CANCER
10.2.6 BRAIN CANCER
10.2.7 LEUKEMIA
10.2.8 OTHERS
10.3 NEURODEGENERATIVE DISEASES
10.4 CARDIOVASCULAR DISEASES
10.5 METABOLIC DISEASES
10.6 OTHERS
11 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY END USE
11.1 OVERVIEW
11.2 CONTRACT RESEARCH ORGANIZATIONS
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.4 RESEARCH CENTERS AND ACADEMIC INSTITUTES
11.5 OTHERS
12 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION
12.1 MIDDLE EAST & AFRICA
12.1.1 SOUTH AFRICA
12.1.2 ISRAEL
12.1.3 SAUDI ARABIA
12.1.4 U.A.E
12.1.5 EGYPT
12.1.6 REST OF MIDDLE EAST AND AFRICA
13 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 NVIDIA CORPORATION
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 MICROSOFT
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 IBM CORP
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 SCHRÖDINGER, INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 BERG LLC
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENTS
15.6 ARDIGEN
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 EXSCIENTIA
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 ARIA PHARMACEUTICALS, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ATOMWISE INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 BENEVOLENT AI
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENTS
15.11 BIOAGE INC.,
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 CLOUD
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 CYCLICA
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.14 DEEP GENOMICS
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 ENVISAGENICS
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
15.16 INSILICO MEDICINE
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 NUMEDII, INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 OWKIN INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 XTALPI INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表のリスト
TABLE 1 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA SERVICES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA DEEP LEARNING IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA NATURAL LANGUAGE PROCESSING (NLP) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA SMALL MOLECULE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA LARGE MOLECULE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA DRUG OPTIMISATION AND RE-PURPOSING PRE-CLINICAL TESTING AND APPROVAL IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA DRUG MONITORING IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA AGGREGATING AND SYNTHESIZING INFORMATION IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA DE NOVO DRUG DESIGN IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA FINDING DRUG TARGETS OF AN OLD DRUG IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA FORMATION & QUALIFICATION OF HYPOTHESES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA UNDERSTANDING DISEASE MECHANISMS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA FINDING NEW DISEASE-ASSOCIATED TARGETS AND PATHWAYS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA METABOLIC DISEASES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 GLOB MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATIONS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA RESEARCH CENTRES AND ACADEMIC INSTITUTES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA ARTIFICIAL SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA ARTIFICIAL MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA ARTIFICIAL NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA ARTIFICIAL IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 49 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 58 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 59 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 60 ISRAEL SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 62 ISRAEL MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 63 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 64 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 65 ISRAEL NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 66 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 67 ISRAEL IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 68 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 69 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 70 SAUDI ARABIA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 72 SAUDI ARABIA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 73 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 74 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 75 SAUDI ARABIA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 76 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 77 SAUDI ARABIA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 78 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 79 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 80 U.A.E SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 82 U.A.E MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 83 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 84 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 U.A.E NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 86 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 87 U.A.E IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 88 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 89 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 90 EGYPT SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 92 EGYPT MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 93 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 94 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 95 EGYPT NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 96 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 97 EGYPT IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 98 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 99 REST OF MIDDLE EAST AND AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: SEGMENTATION
FIGURE 11 THE GROWING NEED TO CURB DRUG DISCOVERY COSTS AND REDUCE TIME INVOLVED IN THE DRUG DEVELOPMENT PROCESS, THE RISING ADOPTION OF CLOUD-BASED APPLICATIONS AND SERVICES, AND THE IMPENDING PATENT EXPIRY OF BLOCKBUSTER DRUGS ARE EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SOFTWARE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET IN 2022 AND 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET
FIGURE 14 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING, 2021
FIGURE 15 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING, 2022-2029 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING, CAGR (2022-2029)
FIGURE 17 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY TECHNOLOGY, 2021
FIGURE 19 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 21 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY DRUG TYPE, 2021
FIGURE 23 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY DRUG TYPE, CAGR (2022-2029)
FIGURE 25 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY DRUG TYPE, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION, 2021
FIGURE 27 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 29 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 30 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY INDICATION, 2021
FIGURE 31 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY INDICATION, 2020-2029 (USD MILLION)
FIGURE 32 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY INDICATION, CAGR (2022-2029)
FIGURE 33 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 34 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY END USE, 2021
FIGURE 35 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY END USE, 2022-2029 (USD MILLION)
FIGURE 36 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY END USE, CAGR (2022-2029)
FIGURE 37 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY END USE, LIFELINE CURVE
FIGURE 38 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: SNAPSHOT (2021)
FIGURE 39 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY COUNTRY (2021)
FIGURE 40 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING (2022-2029)
FIGURE 43 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
